Want to see KYMR full AI Analyst Report?
KYMR Stock Chart & Stats
$87.71
-$0.34(-0.84%)
At close: 4:00 PM EST
$87.71
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$36.65 - $130.05
Previous CloseN/A
Volume48.51K
Average Volume (3M)1.07M
Market Cap
$9.52B
Enterprise Value$7.55K
Total Cash (Recent Filing)$650.93M
Total Debt (Recent Filing)$80.47M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Jul 31, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.58
Shares Outstanding82,257,590
10 Day Avg. Volume658,598
30 Day Avg. Volume1,066,543
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.16
Price to Sales (P/S)167.51
P/FCF Ratio-28.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$130.07Price Target Upside48.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-3.48
Revenue Forecast (FY)$84.46M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a sizable equity base provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports multi-year R&D programs and potential Ph3 starts, and gives management room to pursue partnerships or opportunistic investments without immediate solvency pressure.
Improving Revenue TrendSustained 30%+ TTM revenue growth for a clinical-stage firm reflects expanding collaboration, milestone, or other non-product receipts. This trend signals commercial validation of platform partnerships and partially offsets R&D spend, improving the company’s ability to fund development and attract partners over a multi-quarter horizon.
Accelerated Clinical ExecutionFinishing BROADEN2 enrollment well ahead of plan demonstrates operational execution and strong patient/provider demand for an oral STAT6 degrader. Faster timelines can materially accelerate decision points, shorten cash runway needs per program, and improve the company’s ability to progress to Phase 3 and negotiate partnerships or commercial terms.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow at this magnitude is a structural strain: it forces management to prioritize spending, increases dependence on external financing, and limits optionality across programs. Over several quarters this level of burn can compress runway and pressure deal terms with partners or investors.
Large Recurring Net LossesLarge, persistent net losses indicate the company remains far from breakeven and that R&D plus operating costs materially outpace revenues. This undermines long-term return profiles and means commercial self-sufficiency is distant unless clinical programs rapidly succeed or cost structure changes, creating sustained execution risk.
Ongoing Financing / Dilution RiskGiven limited product revenue, the company historically relies on collaborations and capital raises. Continued high burn and negative earnings make further equity financing likely, which can dilute shareholders and constrain strategic flexibility. This structural financing dependence affects capital allocation over the medium term.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $36.65 and its highest was $130.05 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $9.52B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Jul 31, 2026 which is in 11 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.171.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.73.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 82,257,590 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -0.54%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.07 (48.30% Upside)
$130.07 (48.30% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 104.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
81.75%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
KYMR Stock 12 Month Forecast
Average Price Target
$130.07
▲(48.30% Upside)
Technical Analysis
Protagonist Therapeutics
―
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
12.06% Insiders
36.88% Mutual Funds
0.09% Other Institutional Investors
36.57% Public Companies and
Individual Investors